title: Should monitoring of fibroblast growth factor-23 levels in dialysis patients be a part of routine clinical practice?
authors.affiliation: MetroHealth Medical Center and Case Western Reserve University, Cleveland, Ohio.
authors.forename: Georges
authors.initials: G
authors.lastname: Saab
authors.forename: Mildred
authors.initials: M
authors.lastname: Lam
authors.forename: Sankar D
authors.initials: SD
authors.lastname: Navaneethan
authors.forename: Eduardo
authors.initials: E
authors.lastname: Slatopolsky
mesh_terms: D002113:Calcification, Physiologic / Q000502:physiology; D000089703:Fibroblast Growth Factor-23; D005346:Fibroblast Growth Factors / Q000097:blood*; D006801:Humans; D017674:Hypophosphatemia / Q000097:blood / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy*; D006435:Renal Dialysis
chemical_list: D005346:Fibroblast Growth Factors; D000089703:Fibroblast Growth Factor-23